VDA

Cancer cells can survive and grow becasue they have tumour vasculature to get blood, nutrients and oxygen. As it is, the tumour vasculature is an attractive target for cancer therapy. Now researchers develop 2 kind of drugs targeting angiogenesis which are VTAs (Vascular targeting agents) and VDAs (Vascular disrupting agents). VTAs(Vascular targeting agents) can prevent new blood vessels from forming with on functions on blood vessels that already feed existing tumors.In contrast, VDAs (Vascular disrupting agents) lead to the vascular structure of a solid tumor to collapse so that VDAs (Vascular disrupting agents) can deprive the tumor of blood and oxygen the tumors need to survive, resulting in tumor ischemia and necrosis. Small molecule vascular disrupting agents including flavonoids, tubulin-binding agents are extremely important for both maintaining tumor growth and controlling the tumor environment.

Other Angiogenesis Related Inhibitors

Src FGFR HIF Bcr-Abl Syk FLT3 FAK BTK ANGPTL FLT

Cat.No.	Product Name	Information	Product Use Citations
S1786	Verteporfin	Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.	Nat Commun, 2025, 16(1):4124 Adv Sci (Weinh), 2025, 12(44):e11726 Cell Death Differ, 2025, 10.1038/s41418-025-01446-2
S1537	Vadimezan (DMXAA)	Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. It is also a STING agonist with potential antineoplastic activity, potently inducing IFN-β but relatively low TNF-α expression in vitro. This compound has antiviral activity. Phase 3.	Cell Chem Biol, 2025, 32(2):280-290.e14 Commun Biol, 2025, 8(1):1470 Front Pharmacol, 2025, 16:1528459
S1176	Plinabulin	Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.	J Med Chem, 2022, 65(13):9159-9173 ACS Omega, 2022, 7(25):21465-21472 J Biol Chem, 2019, 294(20):8161-8170

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S1786

Verteporfin

Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

Nat Commun, 2025, 16(1):4124

Adv Sci (Weinh), 2025, 12(44):e11726

Cell Death Differ, 2025, 10.1038/s41418-025-01446-2

S1537

Vadimezan (DMXAA)

Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. It is also a STING agonist with potential antineoplastic activity, potently inducing IFN-β but relatively low TNF-α expression in vitro. This compound has antiviral activity. Phase 3.

Cell Chem Biol, 2025, 32(2):280-290.e14

Commun Biol, 2025, 8(1):1470

Front Pharmacol, 2025, 16:1528459

Verified customer review of Vadimezan (DMXAA)

S1176

Plinabulin

Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.

J Med Chem, 2022, 65(13):9159-9173

ACS Omega, 2022, 7(25):21465-21472

J Biol Chem, 2019, 294(20):8161-8170

Other Angiogenesis Related Inhibitors

Signaling Pathway Map